Eli Lilly announces historic $6 billion pharmaceutical campus near Madison
This is the largest private industrial investment in Alabama history
HUNTSVILLE – Eli Lilly and Company announced plans to build a $6 billion pharmaceutical manufacturing campus in Huntsville, marking the largest private industrial investment in Alabama history, according to officials. The campus will produce advanced active pharmaceutical ingredients for the company’s next-generation medicines and will be located on a newly developed 260-acre site near Interstate 565 and Greenbrier Parkway. Officials said construction is scheduled to begin in 2026, with operations expected to ramp up through 2032. The facility is projected to create 450 full-time positions in engineering, research, technical operations, and quality control, in addition to approximately 3,000 construction jobs during the build-out.
Huntsville Mayor Tommy Battle noted Lilly’s investment reflects the region’s expertise in innovation and science. “Eli Lilly’s decision to invest $6 billion to locate its new active pharmaceutical ingredient production facility in Huntsville is a tremendous vote of confidence in our people and our future,” he said.
Alabama Gov. Kay Ivey emphasized the state’s long-standing role in bioscience and advanced manufacturing. “Huntsville and our entire state have a proven legacy of innovation, and there is no better home for Lilly than right here in Alabama,” she said. Ivey added that the project represents the largest initial investment in Alabama’s history.
Limestone County Commission Chairman Collin Daly said the investment’s effects will extend beyond the construction period. “The jobs and investment that Lilly is making in North Alabama will have a positive impact for generations,” he said.
Eli Lilly evaluated multiple states before ultimately selecting Huntsville, citing its skilled workforce, strong scientific infrastructure, and manufacturing readiness, CEO David A. Ricks said.
“Huntsville’s track record of science and innovation, supported by advanced manufacturing expertise and a skilled workforce, makes Alabama an ideal location for Lilly to expand domestic manufacturing capacity for next-generation medicines,” Ricks said. He added that the investment “strengthens supply chain resilience and ensures reliable access to medicines for patients in the U.S.,” providing strategic benefits nationally.
The campus will feature advanced automation, integrated digital monitoring, and AI-driven manufacturing systems. These innovations position Huntsville as a key hub for domestic medicine production.
The city of Madison issued a statement after the announcement: “This transformational project is set to be the largest economic investment in Alabama’s history, with an estimated $25B impact on our local economy.
“The facility will produce next-generation synthetic medications for diabetes, cancer, and obesity, all manufactured locally and poised to change lives around the world.
“Madison and our region are proud to play a role in this incredible moment for innovation, jobs, and global health.”
